- Can Blood Test Predict Survival in Metastatic Prostate Cancer?
November 25, 2024A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who might stand to benefit from new drug trials. The… - USC Team Counts Circulating Tumor Cells to Predict Treatment Response, Survival in Prostate Cancer
October 11, 2024A team of researchers at the University of Southern California has used a commercial blood test to count circulating tumor cells (CTCs) and predict how prostate cancer patients will respond to certain therapies and their survival outcomes. View full article here. - Blood Test Predicts Outcomes in Newly Diagnosed Metastatic Prostate Cancer
October 9, 2024A blood test that measures the number of circulating tumor cells (CTCs) at the time of metastatic prostate cancer diagnosis can predict treatment response, disease progression, and overall survival, regardless of subsequent therapies over time, shows a study led by University of Southern California (USC) researchers. View full article here. - Circulating Tumor Cell Count and Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
October 7, 2024In metastatic hormone-sensitive prostate cancer (mHSPC), new first-line combination therapies have enhanced overall survival (OS), but clinical outcomes for individual patients vary greatly and are difficult to predict. Peripheral blood circulating tumor cell (CTC) count is the most extensively validated prognostic liquid biomarker in metastatic castration-resistant prostate cancer (mCRPC), and recent studies have suggested that… - Circulating tumor cell count predicts prostate cancer survival, can help tailor treatment
October 7, 2024October 07, 2024 “Prostate cancer is the most common malignancy [among] American men and the second most lethal,” Amir Goldkorn, MD, professor of medicine and biochemistry & molecular medicine at Keck School of Medicine and associate director for translational research at USC Norris Comprehensive Cancer Center, told Healio. “New drugs are emerging, but there are very few assays… - An early blood test can predict survival in patients with metastatic prostate cancer, shows USC study
October 7, 2024The non-invasive test, which measures circulating tumor cells in the blood, can predict treatment response, disease progression and overall survival in men newly diagnosed with metastatic prostate cancer, according to new research led by USC Norris Comprehensive Cancer Center. View full article here. - SWOG's ASCO 2023 preview highlights Goldkorn Lab liquid biopsy research in two abstracts
May 30, 2023SWOG Presents 30 Abstracts at ASCO 2023 | SWOG "Here are highlights from some of the other SWOG work to be presented at ASCO 2023... An analysis of the prognostic value of circulating tumor cell (CTC) counts in patients with metastatic hormone-sensitive prostate cancer (mHSPC) on the SWOG S1216 trial reports that CTC count at… - Liquid Biopsies Featured in National Geographic
February 17, 2023The February issue of National Geographic magazine featured an article providing readers with a broad overview of what liquid biopsies are and what they have the potential to be. Amir was one of three leading scientists in the field interviewed for the article. View it on the website here, or see it linked below. How-liquid-biopsies-have-made-it-easier-to-treat-cancerDownload - Goldkorn Lab presents research into cell-free DNA methylation at ASCO 2022
June 30, 2022The ASCO 2022 annual meeting was held last month, and on June 3rd, the Goldkorn Lab presented an oral abstract showcasing research done in cooperation with SWOG. Using the S1314 neo-adjuvant bladder cancer cohort, researchers from the Goldkorn Lab -- led by Yi-Tsung Lu -- showed that cell-free DNA methylation patterns are a biomarker to… - Amir visits the Uromigos!
June 3, 2022Amir joins Dr. Tom Powles and Dr. Brian Rini on the Kidney Cancer Association's Uromigos podcast to discuss the results of the S1314 clinical trial, specifically how cell-free DNA methylation in bladder cancer can predict if patients will respond to chemotherapy. Listen below!